Latest UCB News & Updates

See the latest news and media coverage for UCB. We track all announcements, press releases, and industry mentions in real time, all in one place.

UCB

Global biopharmaceutical company for neurological and immune‑mediated diseases

ucb.com

Headquarters: Brussels, Belgium
Founded year: 1928
Company type: Private company
Number of employees: 5,000–20,000
Industry: Pharmaceuticals

Last updated Today

Latest news about UCB

In short: UCB raised its 2026 guidance following strong sales growth, acquired Candid Therapeutics for $2.2B, and secured a U.S. drug pricing deal.

Company announcements

July 30 UCB

UCB reported strong half year results for 2026

Total revenue grew 27% to €4.27 billion, with pipeline progress and acquisitions expanding innovation capabilities.

July 30 UCB

UCB reports strong H1 2026 financial results

Total revenue grew 22% to €4.27 billion and adjusted EBITDA rose 68% to €1.74 billion, with updated full-year guidance.

June 17 UCB

UCB completes acquisition of Candid Therapeutics

The $2.2B deal adds cizutamig, a BCMA T-cell engager, to UCB's immunology pipeline.

June 2 UCB

UCB completes acquisition of Neurona Therapeutics

The deal adds Neurona's cell therapy pipeline and entrepreneurial team to UCB's neuroscience portfolio.

Media coverage

September 8 DH Les Sports+

UCB announces an accelerated review procedure in the United States for Cimzia

The US drug agency, the FDA, will accelerate the evaluation of Cimzia, UCB's anti-inflammatory drug, for the treatment...

August 31 Euractiv

Only EU-based drugmaker in Trump's pricing deal keeps Europe guessing on cost

The deal gives Belgium's UCB tariff protection and a clearer US manufacturing foothold, while the company insists its ...

August 26 The Pharma Letter

New Phase III data for UCB's Fintepla in Dravet syndrome

Belgium's largest drugmaker UCB has published new peer-reviewed data in Epilepsia Open which collates findings from three pivotal Phase III trials evaluating the efficacy and...

August 19 Simply Wall St

Is UCB (ENXTBR:UCB) Fully Valued After New FINTEPLA Data In Lennox Gastaut Syndrome? - Simply Wall St News

Why the latest FINTEPLA data matters for UCB stock UCB (ENXTBR:UCB) is in focus after new EpilepsiaOpen data on FINTEPLA in Lennox Gastaut syndrome reported...

Never miss news about UCB

Track UCB and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

UCB competitors & trending companies

Browse news for competitors to UCB and other trending companies.